Epigenetic silencing of TBX1 inactivates the Hippo pathway to potentiate chemoresistance in esophageal squamous cell carcinoma

Zhong Xu, Gang Ma, Ying Shen, Li Tan, Xuejuan Sun, Lei Peng, Weiyan Peng, Lin Ye · 2026

Read Epigenetic silencing of TBX1 inactivates the Hippo pathway to potentiate chemoresistance in esophageal squamous cell carcinoma by Zhong Xu, Gang Ma, Ying Shen, Li Tan, Xuejuan Sun, Lei Peng, Weiyan Peng, Lin Ye (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13473094.txt.

Description

Xu and co-authors found an epigenetic off-switch that helps esophageal cancers resist pre-surgery chemotherapy: methylation silencing of the TBX1 gene. Their 2026 study linked heavy methylation of the TBX1 promoter to nonresponse in patients with esophageal squamous cell carcinoma and then restored the gene in laboratory models.

The clinical backdrop is poor: about 20% of these tumors do not respond to neoadjuvant chemotherapy at all, and more than 50% respond only partially. TBX1 normally switches on the Hippo pathway, a growth brake, by raising MST1 and LATS1 and by loosening the cell's actin skeleton. Restoring TBX1 slowed cell growth, triggered cell death, and made cells sensitive to cisplatin again, while tumors in animals grew less. The authors propose promoter methylation as a warning test.

Catalog record

CREATORZhong Xu, Gang Ma, Ying Shen, Li Tan, Xuejuan Sun, Lei Peng, Weiyan Peng, Lin Ye
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE67 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13473094

Browse the full library · About the Tower of Babel